Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Faculty of Science University of Ostrava Ostrava Czech Republic

Br J Haematol. 2020 Jun;189(6):1136-1140. doi: 10.1111/bjh.16454. PubMed

Zobrazit více v PubMed

Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., Marit, G., Michaux, L., Voillat, L., Renaud, M., Grosbois, B., Guillerm, G., Benboubker, L., Monconduit, M., Thieblemont, C., Casassus, P., Caillot, D., Stoppa, A.M., Sotto, J.J., Wetterwald, M., Dumontet, C., Fuzibet, J.G., Azais, I., Dorvaux, V., Zandecki, M., Bataille, R., Minvielle, S., Harousseau, J.L., Facon, T. & Mathiot, C. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood, 109, 3489-3495.

Basali, D., Chakraborty, R., Rybicki, L., Rosko, N., Reed, J., Karam, M., Schlueter, K., Dysert, H., Kalaycio, M. & Valent, J. (2020) Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. British Journal of Haematology, 189, 1136-1140.

Chari, A., Vogl, D.T., Gavriatopoulou, M., Nooka, A.K., Yee, A.J., Huff, C.A., Moreau, P., Dingli, D., Cole, C., Lonial, S., Dimopoulos, M., Stewart, A.K., Richter, J., Vij, R., Tuchman, S., Raab, M.S., Weisel, K.C., Delforge, M., Cornell, R.F., Kaminetzky, D., Hoffman, J.E., Costa, L.J., Parker, T.L., Levy, M., Schreder, M., Meuleman, N., Frenzel, L., Mohty, M., Choquet, S., Schiller, G., Comenzo, R.L., Engelhardt, M., Illmer, T., Vlummens, P., Doyen, C., Facon, T., Karlin, L., Perrot, A., Podar, K., Kauffman, M.G., Shacham, S., Li, L., Tang, S., Picklesimer, C., Saint-Martin, J.R., Crochiere, M., Chang, H., Parekh, S., Landesman, Y., Shah, J., Richardson, P.G. & Jagannath, S. (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. The New England Journal of Medicine, 381, 727-738.

Gay, F. & Goldschmidt, H. (2019) Do we need cytogenetics in the follow-up of multiple myeloma? British Journal of Haematology, 185, 399-401.

Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., Popkova, T., Benkova, K., Richterova, P., Plonkova, H., Zuchnicka, J. & Broskevicova, L. (2019) Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t (11; 14). American Journal of Hematology, 94, E35.

Kumar, S., Kaufman, J.L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., Punnoose, E.A., Alzate, S., Dunbar, M., Xu, T., Agarwal, S.K., Enschede, S.H., Leverson, J.D., Ross, J.A., Maciag, P.C., Verdugo, M., Touzeau, C. (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 130, 2401-2409.

Lonial, S., Lee, H.C., Badros, A., Trudel, S., Nooka, A.K., Chari, A., Abdallah, A.O., Callander, N., Lendvai, N., Sborov, D., Suvannasankha, A., Weisel, K., Karlin, L., Libby, E., Arnulf, B., Facon, T., Hulin, C., Kortüm, K.M., Rodríguez-Otero, P., Usmani, S.Z., Hari, P., Baz, R., Quach, H., Moreau, P., Voorhees, P.M., Gupta, I., Hoos, A., Zhi, E., Baron, J., Piontek, T., Lewis, E., Jewell, R.C., Dettman, E.J., Popat, R., Esposti, S.D., Opalinska, J., Richardson, P. & Cohen, A.D. (2019) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet Oncology. [Epub ahead of print]. DOI: https://doi.org/10.1016/S1470-2045(19)30788-0.

Mateos, M.-V., Cavo, M., Blade, J., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Pour, L., Cook, M., Grosicki, S., Crepaldi, A., Liberati, A.M., Campbell, P., Shelekhova, T., Yoon, S.-S., Iosava, G., Fujisaki, T., Garg, M., Krevvata, M., Chen, Y., Wang, J., Kudva, A., Ukropec, J., Wroblewski, S., Qi, M., Kobos, R. & San-Miguel, J. (2019) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet, 395, 132-141.

Mihalyova, J., Jelinek, T., Growkova, K., Hrdinka, M., Simicek, M. & Hajek, R. (2018) Venetoclax: A new wave in hematooncology. Experimental Hematology, 61, 10-25.

Moreau, P., Harrison, S., Cavo, M., De La Rubia, J., Popat, R., Gasparetto, C., Hungria, V.T.M., Salwender, H., Suzuki, K., Kim, I., Gay, F., Mikala, G., Punnoose, E.A., Hong, W.-J., Sood, A., Jalaluddin, M., Ross, J.A., Ward, J.E., Maciag, P.C. & Kumar, S.K. (2019) Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 134, 1888-1888.

Moreau, P., Chanan-Khan, A., Roberts, A.W., Agarwal, A.B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E.A., Cordero, J., Munasinghe, W., Jia, J., Salem, A.H., Freise, K.J., Leverson, J.D., Enschede, S.H., Ross, J.A., Maciag, P.C., Verdugo, M. & Harrison, S.J. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood, 130, 2392-2400.

Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P. & Rodriguez, I. (2019) The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clinical Cancer Research, 25, 3176-3187.

Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B.K., Chaturvedi, V., Bennett, F., Pollock, P.M., Trent, J.M., Hendrix, M.J.C., Rizzo, P., Miele, L. & Nickoloff, B.J. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Research, 65, 6282-6293.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M.V., Turka, A., Lam, L.-P., Morgan, R.A., Friedman, K., Massaro, M., Wang, J., Russotti, G., Yang, Z., Campbell, T., Hege, K., Petrocca, F., Quigley, M.T., Munshi, N. & Kochenderfer, J.N. (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. The New England Journal of Medicine, 380, 1726-1737.

Royer, B., Minvielle, S., Diouf, M., Roussel, M., Karlin, L., Hulin, C., Arnulf, B., Macro, M., Cailleres, S., Brion, A., Brechignac, S., Belhadj, K., Chretien, M.L., Wetterwald, M., Chaleteix, C., Tiab, M., Leleu, X., Frenzel, L., Garderet, L., Choquet, S., Fuzibet, J.G., Dauriac, C., Forneker, L.M., Benboubker, L., Facon, T., Moreau, P., Avet-Loiseau, H. & Marolleau, J.P. (2016) Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective Phase II study of the intergroupe francophone du myélome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 2125-2132.

Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J.D., Souers, A.J., Maïga, S., Béné, M.C., Moreau, P., Pellat-Deceunynck, C. & Amiot, M. (2014) The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia, 28, 210-212.

Touzeau, C., Ryan, J., Guerriero, J., Moreau, P., Chonghaile, T.N., Le Gouill, S., Richardson, P., Anderson, K., Amiot, M. & Letai, A. (2016) BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia, 30, 761-764.

Touzeau, C., Maciag, P., Amiot, M. & Moreau, P. (2018) Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia, 32, 1899-1907.